Logo image of PRGO

PERRIGO CO PLC (PRGO) Stock Price, Forecast & Analysis

USA - NYSE:PRGO - IE00BGH1M568 - Common Stock

14.44 USD
-0.49 (-3.28%)
Last: 11/7/2025, 8:09:26 PM
14.59 USD
+0.15 (+1.04%)
After Hours: 11/7/2025, 8:09:26 PM

PRGO Key Statistics, Chart & Performance

Key Statistics
Market Cap1.99B
Revenue(TTM)4.37B
Net Income(TTM)-80.30M
Shares137.58M
Float136.97M
52 Week High30.93
52 Week Low14.17
Yearly Dividend1.12
Dividend Yield7.77%
EPS(TTM)2.9
PE4.98
Fwd PE4.54
Earnings (Next)02-23 2026-02-23/amc
IPO1991-12-17
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PRGO short term performance overview.The bars show the price performance of PRGO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

PRGO long term performance overview.The bars show the price performance of PRGO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PRGO is 14.44 USD. In the past month the price decreased by -32.05%. In the past year, price decreased by -45.22%.

PERRIGO CO PLC / PRGO Daily stock chart

PRGO Latest News, Press Relases and Analysis

PRGO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO42.04874.88B
JNJ JOHNSON & JOHNSON17.97449.32B
MRK MERCK & CO. INC.9.79215.51B
PFE PFIZER INC7.63138.90B
BMY BRISTOL-MYERS SQUIBB CO7.1295.03B
ZTS ZOETIS INC18.9753.29B
RPRX ROYALTY PHARMA PLC- CL A9.3822.49B
VTRS VIATRIS INC4.3411.80B
ELAN ELANCO ANIMAL HEALTH INC22.3910.68B
CORT CORCEPT THERAPEUTICS INC83.777.77B
AXSM AXSOME THERAPEUTICS INCN/A6.89B
CRNX CRINETICS PHARMACEUTICALS INN/A3.77B

About PRGO

Company Profile

PRGO logo image Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

Company Info

PERRIGO CO PLC

The Sharp Building, Hogan Place, Dublin 2

DUBLIN DUBLIN 49010 IE

CEO: Murray S. Kessler

Employees: 8379

PRGO Company Website

PRGO Investor Relations

Phone: 3532696738451

PERRIGO CO PLC / PRGO FAQ

What does PERRIGO CO PLC do?

Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.


What is the current price of PRGO stock?

The current stock price of PRGO is 14.44 USD. The price decreased by -3.28% in the last trading session.


Does PERRIGO CO PLC pay dividends?

PERRIGO CO PLC (PRGO) has a dividend yield of 7.77%. The yearly dividend amount is currently 1.12.


What is the ChartMill technical and fundamental rating of PRGO stock?

PRGO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the analyst forecast for PRGO stock?

10 analysts have analysed PRGO and the average price target is 32.3 USD. This implies a price increase of 123.68% is expected in the next year compared to the current price of 14.44.


Can you provide the PE ratio for PRGO stock?

The PE ratio for PERRIGO CO PLC (PRGO) is 4.98. This is based on the reported non-GAAP earnings per share of 2.9 and the current share price of 14.44 USD.


What is the expected growth for PRGO stock?

The Revenue of PERRIGO CO PLC (PRGO) is expected to decline by -1.19% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


PRGO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PRGO Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PRGO. There are concerns on the financial health of PRGO while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRGO Financial Highlights

Over the last trailing twelve months PRGO reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 16.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -0.8%
ROE -1.8%
Debt/Equity 0.81
Chartmill High Growth Momentum
EPS Q2Q%-1.23%
Sales Q2Q%-4.06%
EPS 1Y (TTM)16.47%
Revenue 1Y (TTM)-6.06%

PRGO Forecast & Estimates

10 analysts have analysed PRGO and the average price target is 32.3 USD. This implies a price increase of 123.68% is expected in the next year compared to the current price of 14.44.

For the next year, analysts expect an EPS growth of 18.61% and a revenue growth -1.19% for PRGO


Analysts
Analysts78
Price Target32.3 (123.68%)
EPS Next Y18.61%
Revenue Next Year-1.19%

PRGO Ownership

Ownership
Inst Owners105.83%
Ins Owners0.45%
Short Float %8.39%
Short Ratio6.8